BMY vs BIIB — Key Metrics
| Metric | BMY (BRISTOL MYERS SQUIBB CO) | BIIB (BIOGEN INC) |
|---|---|---|
| Price | 59.56 | 251.41 |
| Market Cap | 121.75 Billion | 37.16 Billion |
| P/E (TTM) | 13.15 | 106.53 |
| P/B (Quarterly) | 5.362 | 1.907 |
| P/S (TTM) | 2.43 | 3.61 |
| Net Profit Margin (TTM) | 18.5 | 3.4 |
| Gross Margin (TTM) | 69.2 | 74.0 |
| ROE (TTM) | 43.9 | 1.9 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Greatly Outperform
Greatly Outperform
Recommendation Summary
Both stocks are projected to significantly outperform the market over the next year. If you have to make a choice, Upfront Recommendation: BMY.
Financial Metrics
| BMY | Metrics | BIIB |
|---|---|---|
| $59.56 | Price | $251.41 |
| — | Market Capitalization | — |
| 13.15 | Price to Earnings Ratio | 106.53 |
| 2.43 | Price to Sales | 3.61 |
| 13.11 | Price to FCF Ratio | 18.09 |
| 3.51 | Price to Gross Profit | 4.88 |
| 11.53 | Price to R&D | 17.27 |
| 4.09 | Price to Current Assets | 4.9 |
BMY vs BIIB at a glance
Bristol Myers Squibb CO (BMY) and Biogen INC (BIIB) are both Drug Manufacturers - General companies in the Healthcare sector. BMY is the larger, at $121.7 billion in market value against $37.2 billion for BIIB, about 3.3 times the size.
On trailing-twelve-month figures, BMY trades at 13.2 times trailing earnings and BIIB at 106.5; net profit margins are 18.5% and 3.4%.
The Upfront Investment model currently rates both Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.